

# **Abstract Submission Tutorial**

**Step-by-Step Instructions with Screen Shots** 



## **Deadlines**

## Friday, December 6, 2019, 11:59 pm, U.S. ET.

After the December 6 deadline, the start of any new abstracts will not be allowed; no exceptions.

#### Sunday, December 8, 2019, 11:59 pm, U.S. ET.

Abstracts may not be modified, submitted or resubmitted after the December 8 modification deadline; no exceptions.

DO NOT WAIT UNTIL THE DEADLINES TO BEGIN A DRAFT ABSTRACT, TO MAKE DRAFT REVISIONS OR TO SUBMIT AN ABSTRACT FOR REVIEW. YOU MAY NOT BE ABLE TO RECEIVE ASSISTANCE WITH YOUR SUBMISSION, IF NEEDED, PRIOR TO THE DEADLINE(S).



## **Browser requirements:**

- Chrome is the preferred browser.
- If you are using Internet Explorer to log in to the abstract submission site, it MUST be IE Version 10.0 or greater.
- Set your browser to <u>Always Allow Pop-ups</u> for the abstract submission site.
- If you are unable to login using your current browser, use a different browser and/or clear the browser's cache.
- The online abstract submission site is supported by the following operating systems and browsers:

Windows:	Mac OS X:
Internet Explorer 10.0	Firefox
Internet Explorer 11.0	Chrome
Microsoft Edge	Safari 9.0.3
Firefox	
Chrome	Android 4.3 and above:
Safari 9.0.3	Chrome
	<u>iOS7:</u>
	C C '



## **Abstract Submission Policies & Procedures**

- Abstracts are limited to 2500 characters and spaces for title, abstract body and image caption(s). Therefore, it is important to craft your abstract submission for clarity and concision.
  - Review the <u>Successful Abstract Submission Guidelines</u>, with tips on including complete data and samples of top-scoring abstracts.
- Read the <u>Abstract Policies and Procedures</u>
- Familiarize yourself with the <u>Abstract Rejection Criteria</u>.
- A First Author must receive approval from the Principal Investigator for submission of the work in the abstract for presentation at the 2019 ARVO Annual Meeting.
- Submission of your abstract indicates your understanding of, and agreement to, all 2019 abstract policies, procedures and guidelines.



## **Member Login Steps**

- 1. You must be an ARVO Member with dues paid through 2020. <u>Renew</u> your membership or join ARVO prior to abstract submission.
- 1. Select the link at the bottom of the <u>Annual Meeting Abstracts</u> web page to access the Abstract Submission Login page.
- Log in using your ARVO Membership/Account Email Address and Password. WARNING: First (submitting) Authors who submit an abstract using another member's Login will be disqualified from submission.
- 3. If you use the Forgot password? feature, a new password that will be sent to your email will be case sensitive; please be sure to enter each character exactly as it appears in your email. If you continue to have problems logging into the system, please email arvo@arvo.org.

# ARVO Submission Login Please sign in using your email address and ARVO password. Only your ARVO login email and password can be used to sign in again from this login page. Once in the Submission site, recommend you do not change your submission site user ID and password unless prompted by the system. If you are using Internet Explorer, it must be IE 9+ to login to the online abstract submission site. Other compatible browsers include Mozilla Firefox 32+, Google Chrome 37+ and Safari 6+. Email Address: yourEmail@address.org Password: Sign n now + Forgot password?



#### journalofvision.org | tvstjournal.org

## Member Login Steps, cont.

#### Select 'Please continue' from the next screen to enter the submission site.

#### **ARVO Submission Login**





#### | journalofvision.org | tvstjournal.org

6

## **Submission Account Steps**

- Confirm/update your submission account's General and Contact
  Information.
  - Select the red arrow by your name in the upper right page header.
  - If you update your name or email, you must also submit the same update(s) to <u>arvo@arvo.org</u> to update your ARVO membership account record as well.

ScholarOne A	\bstracts™						Lorraine Birks 🔻	Messages (trew) -	Help Log Out
			ARVC RESEARCH: A VISION OF H	D2016 MAY 1 - 5   SEAT		SUBMISSION Abstract submiss October 15 – December 4, 20	General Information Contact Information		
Welcome	Submission	Review	Decision	Session	Admin	Planner	-		
Contact Infr	ormation				۷	Velcome to the	ARVO Annua	al Meeting	
Web	http://ww	/w. arvo. oro/ C	2			Program S	Submission	Site	
			-	To view all email notifications and/or invitations that have been sent to you through this submission site - Select the MESSAGES tab in the upper right of this page (New) will be displayed on the tab if there are any unread communications.			ission site		



## **Submission Account Steps, cont.**

Select the Submission Tab to begin Abstract Submission.

~	ARVO 2017 GLORA GAVECTORS IN VISION FEATURE IN UNCONFECTION OF INFORMATION OF INF
Welcome Submission	
View Submissions	View Submissions
Create New Submission	<ul> <li>VIEW SUDTINISIONS</li> <li>2017 Annual Meeting Submissions</li> <li>INVITED SPEAKER SUBMISSIONS</li> <li>If you have been invited to speak during ARVO 2017, a draft submission has already been created</li> <li>If you are presenting in more then one invited speaker session, each draft submission will be listed</li> <li>DO NOT CREATE A NEW SUBMISSION.</li> <li>DO NOT DELETE ANY INVITED SPEAKER DRAFT(S) that have been created for you.</li> <li>Soroll down to the bottom of this page to access your Invited Speaker draft submission(s).</li> <li>Click the ACTION drop-down and select Edit Draft to begin your edits.</li> <li>Please carefully read over the Full Instructions linked from the top of that page before beginning to Abstracts must be work that has not been submitted for publication prior to the abstract submission submission deadline, an author is at liberty to submit their abstract to a journal for publication constants.</li> <li>Abstracts must be work that has not been submitted for musicating a new Draft abstract.</li> <li>Sunday, December 4, 2016, 11:59 pm U.S. ET is the deadline for stating a new Draft abstract.</li> <li>Sunday, December 4, 2016, 11:59 pm U.S. ET is the deadline for making additional modifications and Submitting or Re-submitting it to be reviewed.</li> <li>To access a previously started draft or an abstract in submission status, scroll to the bottom column, select the appropriate option for that abstract.</li> <li>DO NOT use Create New Submission to return to a previously started draft can be submitted for publication prior on the assumitted or proposal submission.</li> <li>Friday, December 2, 2016, 11:59 pm U.S. ET is the deadline for SIG Meeting Proposal submission for that abstract in submission status, scroll to the bottom column, select the appropriate option for that abstract.</li> <li>You may create multiple drafts during the submission process, but only one draft can be submitted for special Interest Groupy (SIG) SUBMISSIONE</li> <li>Friday, December 2, 2016, 11:59 pm U.S.</li></ul>
	alo



#### alofvision.org | tvstjournal.org

## **Abstract Submission – Starting a Submission**



- Select the **Submission** tab at the top of the page.
- Select Create New Submission from the left sidebar to begin a new abstract. You will be taken to the Title/Body Step.
- Select View Submissions from the left sidebar to access a previously started draft or abstract in submission status. Scroll to the bottom of the page and select the appropriate option for that abstract from its Action column.
- DO NOT use Create New Submission to return to a previously started draft.
- You may create multiple drafts during the submission process, but only one draft can be submitted for review.



## **Abstract Submission - Instructions**

- Full Instructions at the top of each Step page links to <u>Abstract Policies and</u> <u>Procedures</u>.
- The Information icon<sup>
   •</sup> next to each topic header provides submission tips and reminders throughout the site.

ality abstracts describing ori ent of hypothesis, an explan- their implications. In submitted for publication p is at liberty to submit their a act submission for clar Guidelines.pdf offers tij ur understanding of, and ag	iginal, unpublished research re ation of methods, a report of d prior to the abstract submission abstract to a journal for publica ity, concision and with su ps on including complete o	esults. Abstract ata that unequivocally test n deadline. After the ation consideration. Ifficient data. data and samples of	
n submitted for publication p is at liberty to submit their a act submission for clar Guidelines.pdf offers tij ur understanding of, and ag	prior to the abstract submission abstract to a journal for publica ity, concision and with su ps on including complete o	n deadline. After the ition consideration. Ifficient data. Iata and samples of	
act submission for clar Guidelines.pdf offers tip ur understanding of, and ag	ity, concision and with su ps on including complete o	ifficient data. data and samples of	
ur understanding of, and ag			
your abstract submission.	reement to, all 2016 abstract po	olicies and procedures.	
s.pdf			
nal tool with screen shots of th upper right corner of this page. e viewed throughout the site by	e submission site. v clicking on the Information icon v	next to a topic header.	
es for the title, abstract body text a acter count. iculate the number of characters a i header bar of each page. by using its circle icon or the Save an excessive character count, you	ind image captions of your submission and spaces. e button at the bottom of the page. u must return to the Title/Body step an	n. Images and the optional Ind reduce your text to the 2500	
ton during the submissi	on process. Use the left na	v Step listing to return	The Association in Vision and Op
	a tool with screen shots of th upper right corner of this page e viewed throughout the site by es for the title, abstract body text a scler count. Iculate the number of characters i header bar of each page. by using its circle icon or the Saw an excessive character count, yo ton during the submissi	al tool with screen shots of the submission site. upper right corner of this page. e viewed throughout the site by clicking on the Information icon es for the title, abstract body text and image captions of your submission acter count. Iculate the number of characters and spaces. header bar of each page. by using its circle icon or the Save button at the bottom of the page. an excessive character count, you must return to the Title/Body step ar ton during the submission process. Use the left na	a lool with screen shots of the submission site. upper right corner of this page. a viewed throughout the site by clicking on the Information icon ● next to a topic header. es for the title, abstract body text and image captions of your submission. Images and the optional acter count. Iculate the number of characters and spaces. header bar of each page. by using its circle icon or the Save button at the bottom of the page. an excessive character count, you must return to the Title/Body step and reduce your text to the 2500 ton during the submission process. Use the left nav Step listing to return

## Abstract Submission Saving Data & Completing Steps

- Select Save at the bottom of the page to save data entered and remain on the same Step.
- Select Save & Continue to proceed to the next Step in the submission process.

none			
Previous S	ep	Save Save & Continue >	



#### Abstract Submission – Saving Data & Completing Steps, cont.

- If the Step has not been completed, you will receive a Step Incomplete pop-up warning listing data still needed to complete the Step.
  - Select Close to return and complete the Step.
  - Select Save & Continue to proceed to the next Step.
  - You can return later to complete any Step by selecting that Step from the left sidebar.
- When you successfully complete and save a Step, a checkmark will appear in the left sidebar for that step.

		📃 S1 Sites 🔘 ARV	D - The Associa 🔥 NetFor	um 🛄
	Total Characters: 93 out of		ScholarOne Abstracts™	
	escribing original, unpublished rese			
Step Incomplete	× accep		Welcome Submission	* Revi
Please Close this window and contect the following errors to return to this step at a content time:	or click Save & Continue		View Submissions	>
The "Results" section of the abstract is missing.	e ##Ab t subm		Create New Submission	
1 Clara	Same & Constitute N		✓ Step 1: Submission type	>
Citose	page a		Step 2: Title/Body	>
			Step 3: Details	>
			Step 4: Author	>
			Step 5: Affirmations	>
Carrier and the rest of the re			Stop 8: Douisou 8 Submit	

## **Abstract Submission:** Step 2: Title/Body

The maximum abstract length (character count) is 2500 characters and spaces in the abstract title, abstract body and image captions.

 Review the <u>Successful Abstract Submission Guidelines</u>, with tips on including complete data and samples of top-scoring abstracts.

Type or copy-and-paste the title and body of your abstract into the text boxes provided: Title, Purpose, Methods, Results, Conclusions.

Enter the title in sentence case. Do not add a period at the end of your title. Do not put the title in all caps, quotation marks or all bold.

Enter your abstract body using the four distinct text boxes that have pre-populated headers: Purpose, Methods, Results, Conclusions.

- Do not repeat these headers within the text boxes.
- Be careful to ensure that your text is correctly entered to appropriately correspond with each distinct text box.



## Abstract Submission: Step 2: Title/Body, cont.

- Special Characters: In most cases, Greek letters and other special characters will transfer from your word processing software.
- A Special Characters tool is available if you need a special character that you are unable to find in your word processor.
- Italics, subscript, superscript will not copy from Word document text. Use the tool bar provided with each text box to apply these features to your text.
- Do not include diagrams, tables, boxes or borders. A diagram or
- table can be included with your submission as an image.



## Abstract Submission: Step 2: Title/Body, cont.

#### Layman Abstract - Optional

- Provide an optional 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.
- Submissions with a layman abstract may be promoted to the public and press by ARVO Staff.

Layman Abstract (optional): Provide a 50-200 word description of your work that non-scientists can understand. Describe the big picture and the implications of your findings, not the study itself and the associated details.

#### O Edit





## **Abstract Submission : Step 2: Title/Body, cont.** Images

Abstract submission may include a maximum of two (2) images.

- First Browse to select your image.
- Second Upload the chosen image.
- Your image will preview on the page.

#### Image Specs:

- JPEG or GIF format only
- 600 dpi minimum resolution
- 1MB max file size
- 3.25" max image width
- 6" max image height



## Abstract Submission: Step 2: Title/Body, cont.

#### Images, cont.

- You may add a caption (optional) to your image. Characters and spaces in an image's caption are included in the abstract's Total Characters count.
- Total Characters count at the top of page will include image(s) caption(s) after you submit the caption.

Images O Edit			
Choose Image IMAGE NAME No image selected.	Caption		ID: 2638305
Chosen Image(s)	BIUx, x* X ⓑ ʾ @ @ ♠ ♪ Ω X	Total Characters: 20 out of 2,500 C	Full Instructions
1 DSC06815.JPG Q Original	Close Chreviaus Step	Submit Caption 2	

## Abstract Submission: Step 2: Title/Body, cont.

## **Total Characters**

- There is a limit of 2500 characters and spaces for the title, abstract body text and image captions of your submission.
- The current Total Characters displays at top of each page.
- Total Characters will not update until you select Save or Save & Continue at the bottom of the page.

Step 1: Title/Body			ID: 26383
Deadline: Dec 2, 2016 11:59 PM U.S. EST	Contact Name: Mouse Test	Total Characters: 20 out of 2,500 C	Full Instructions

	-

#### **Presentation Type**

Select your **Presentation Type** preference from the drop down menu.

**Paper #1, Poster #2** – This abstract may be scheduled as a Paper (oral) but will likely be scheduled as a Poster.

**Poster #1, Paper #2** – This abstract will likely be scheduled as a Poster but may be scheduled as a Paper (oral).

**Poster Only** – This abstract will only be scheduled as a Poster. (Paper Only is not an available option.)

#### Step 2: Details

Deadline: Dec 2, 2016 11:59 PM U.S. EST

#### URGENT: Travel Grant and Award Appl

- Be sure to record your responses by clicking of Before saving and continuing from this Details correctly recorded.
- Do not change the radio button from Application.
- If you are withdrawing your application, r Decline.

#### ALL Abstract Submissions

- One (1) Reviewing Code that best describer
- You must also populate the Section drop-

Refer to the 2017 Reviewing Codes.pdf list.

\* = Required Fields

#### Presentation Type 0

Type

None selected

None selected #1 Poster, #2 Paper #1 Paper, #2 Poster Poster Only

## **Reviewing Code**

- Select one <u>Reviewing Code</u> from the drop-down menu that **best** represents the content of your abstract.
- Select the corresponding Section or Cross-sectional Group for that Reviewing Code.

**Note:** See <u>2020 Reviewing Codes</u> link on Annual Meeting / Abstracts web page to view the list prior to the start of your abstract submission.

*Presentation Type 🛛 Edit	
Туре	
#1 Paper, #2 Poster ▼	
*Reviewing Code	
Reviewing Code	
None selected	
None selected 1010 accommodation and presbyopia, in vivo and in vitro - VI 1020 adaptive optics: imaging and visual performance - VI 1030 aging vision - VI 1040 allergic conjunctivitis - IM 1050 amblyopia: animal models and basic mechanisms - EY 1070 amblyopia: screening and epidemiology - EY 1070 amblyopia: BE	1
1090 AMD and VEOr - RE         1090 AMD novel therapies (i.e. except anti-VEGF) - RE         1110 AMD: biochemical and molecular disease mechanisms - BI         1120 AMD: cell biology - RC         1130 AMD: cellical research - RE         1140 AMD: peridetic studies - GEN         1150 AMD: genetic studies - GEN         1160 AMD: memory disclogy - IL         1160 AMD: genetic studies - GEN         1170 AMD: new drugs, delivery systems, and mechanisms of action - PH         1180 AMD: preclinical studies - RC	
Decline	

Гуре	
#1 Paper, #2 Poster *	
Reviewing Code o	
Reviewing Code	* Section
1200 accommodation and pre: •	Nothing selected *
Awards o	Nothing selected Visual Psychophysics/Physiological Optics

#### **Travel Grants & Awards (Optional)**

- □ ARVO and ARVO Foundation Travel Grants
- ARVO / Alcon Early Career Clinician-Scientist Research Award
- MIT Outstanding Poster Award
- Select **Details & Conditions** to determine if you are eligible to apply for a travel grant and/or an award.

*Awards • Edit	Award Details & Conditions
DECISION AWARD NAME	AWArd ARVO and ARVO Foundation Travel Grants
<ul> <li>Apply ARVO and ARVO Foundation Travel Grants</li> <li>Decline Details &amp; Conditions </li> </ul>	Details For descriptions of Travel Grants, click here. Travel grants provide partial travel support to investigators who have an accepted abstract for the 2015 ARVO Annual Meeting and whose research findings in the abstract are considered to be of high interest to the vision and ophthalmology research community. The ARVO Annual Meeting provides a unjue concerning for trainage and early career interestingators to the vision and ophthalmology research with leaders in the fields and receive anewnet ho
Apply ARVO / Alcon Early Career Clinician-Scientist Research Award     Decline Details & Conditions	These Travel Grants are awarded to those who:
Apply ARVO Members-in-Training Outstanding Poster Award     Decline Details & Conditions	<ul> <li>are in full-time training or completed after June 2011</li> <li>meet the criteria of travel grants</li> <li>who have not previously received any of the following:         <ul> <li>any ARVO Annual Meeting Travel Grant whether supported by ARVO, The ARVO Foundation for Eye Research, or a 3rd party, such as NEI, Retina Research Foundation, or Nicolas Bazan</li> <li>an International Chapter Affiliate supported travel grant to the ARVO Annual Meeting</li> <li>an ARVO/Alcon Early Career Clinician Scientist Award</li> <li>a Developing Country Eye Researcher Fellowship (DCERF) Travel Award</li> </ul> </li> </ul>
	Note: If you do not fit into these categories you are NOT eligible for a travel grant. You must close this window, check 'Decline' for the Travel Grants, and click Save & Continue to complete your abstract submission.

#### Travel Grants & Awards (Optional), cont.

- Select the Apply button for the Travel Grants or the Award(s) that you want to apply to.
- Answer all questions on the application.
- All questions designated with a red \* are required.
- To complete your application(s), you must Agree to the affirmation statements at the end of each application.

DECISION	AWARD NAME
<ul><li>Apply</li><li>Decline</li></ul>	ARVO and ARVO Foundation Travel Grants Details & Conditions
<ul><li>Apply</li><li>Decline</li></ul>	ARVO / Alcon Early Career Clinician-Scientist Research Award Details & Conditions 🗹
<ul><li>Apply</li><li>Decline</li></ul>	ARVO 2015 Members-in-Training Outstanding Poster Award Details & Conditions I

DECISION	AWARD NAME				
<ul><li>Apply</li><li>Decline</li></ul>	ARVO and ARVO Foundation Travel Grants Details & Conditions I				
	* To apply for this award, please neck the following:				
	* Travel Grant: Gender				
	Please select one:				
	None selected				
	* Travel Grant: Ethnicity				
	Please select one:				
	None selected				
	Travel Grant: Other Ethnicity				
	Please provide other ethnicity information in the field below				
	* Travel Grant: Citizenship				
	Please select ALL that apply:				
	United States and its Territories: Citizen				
	United States and its Territories: Permanent Resident United States and its Territories: Student Vice				
	United States and its Territories, Student Visa     Europe: Any European Country				
	Europe: Eastern European Country				
	Europe: Italy				
	on.org   tvstjournal				

Travel Grants & Awards (Optional), cont.

- **Do not change the radio button from Apply back to Decline** after completing an application, **unless** you are withdrawing your application.
- If you are withdrawing your application, first remove all of your responses from the application then change the radio button from Apply to Decline.

	DECISION AWARD NAME	
*Awards   Edit	Apply ARVO and ARVO Foundation Travel Grants     Decline Details & Conditions C*	
DECISION AWARD NAME  Apply ARVO and ARVO Foundation Travel Grants  Details & Conditions C*	<ul> <li>To apply for this award, please check the following:</li> <li>Travel Grant: Gender</li> <li>Please select one:</li> <li>None selected</li> </ul>	
<ul> <li>Apply ARVO / Alcon Early Career Clinician-Scientist Research Award</li> <li>Decline Details &amp; Conditions C*</li> </ul>	* Travel Grant: Ethnicity Please select one: None selected	
<ul> <li>Apply ARVO 2015 Members-in-Training Outstanding Poster Award</li> <li>Decline Details &amp; Conditions ☑*</li> </ul>	Travel Grant: Other Ethnicity Please provide other ethnicity information in the field below	
	Travel Grant: Citizenship     Please select ALL that apply:     United States and its Territories: Citizen     United States and its Territories: Permanent Resident	The Association for Research in Vision and Ophthalmology
	United States and its Territories: Student Visa     Europe: Any European Country     Europe: Eastern European Country	on.org   tvstjournal.org

Describe the type of research in your abstract:

## Type of Research

How would you describe the type of research in your abstract submission? Note: There is no ARVO definition for these terms.

Translational

v



**Clinical Trial Registration** 

To determine if the study results presented in your submission are from a clinical trial, consider the following three questions:

1. Is the study prospective?

2. Does the study involve 2 or more groups of human subjects?

3. Does the study involve a therapeutic intervention in human subjects? Any kind of intervention is included, for example, but not limited to: medical, surgical, psychological and sociological.

\* If the answer is "No' to any of these questions, the study does not meet the current definition of a clinical trial and does not need to be registered. Select "No" below.
\* If the Answer is "Yes" to all three questions, the study meets the definition of a clinical trial and must be registered. Select "Yes" below and provide the study's registration information.



## **Clinical Trial Registration, cont.**

- 1. If your abstract reports on a clinical trial, select Yes for your registry URL.
- 2. If Yes Other is selected, you must enter your registry URL in the Other Registry Site text box.
- 3. If your clinical trial is registered with more than one site, you only need to provide registration details for one of the sites.
- 4. If your work does not report on a clinical trial, you must select NO.

#### \* CLINICAL TRIAL REGISTRATION

\* Please answer the information below regarding Clinical Trial Registration. \* If there are multiple Clinical Trial Registrations for one submission, select only one.

\* Clinical trials with two or more groups of subjects require registration with a publicly accessible clinical trials registry that is approved by the World Health Organization (WHO).

\* All submissions that describe results from a clinical trial with two or more groups of subjects must include the registry site and registration number of the trial, the date the trial was registered, and the date the trial began.

To determine if the study results presented in your submission are from a clinical trial, consider the following two questions and refer to the ARVO Statement on Registering Clinical Trials about the ARVO policy.

1. Does this study involve a therapeutic intervention in human subjects? (The intervention may be of any kind, e.g., medical, surgical/laser, or psychological/sociological.)

2. Is the study prospective? (A study planned to observe events that have not yet occurred.)

\* If the answer is "No' to either question, then the study does not meet the current definition of a clinical trial, and does not need to be registered. Select "No" below.

\* If the Answer is "Yes" to both questions, then the study does meet the definition of a clinical trial, regardless of the number of subjects involved or if it involves comparison groups (i.e., different doses of a drug, or treatment and control groups) and must be registered. Select "Yes" below and provide the study's Registry data.

#### \* Does the research presented in your submission meet the above definition of a clinical tria

None selected	
None selected Yes - http://www.anzctr.org.au Yes - http://www.clinicaltrials.gov Yes - http://srctn.org Yes - http://srctn.org Yes - http://cleufract.ema.europa.eu Yes - http://coprtal.niph.go.jp Yes - http://www.slctr.lk	
Yes - http://www.trialregister.nl/trialreg/index.asp Yes - http://www.ensaiosclinicos.gov.br Yes - http://ncrc.cdc.go.kr/cris/index.jsp Yes - http://ctri.nic.in/Clinicaltrials/login.php Yes - Other No	istration Number, date trial began, and date

\* Does the research presented in your submission meet the above definition of a clinical trial?

Yes - Other

Yes - Other

If 'Other' Registry Site Selected, Enter Registry Site



#### Clinical Trial Registration, cont.

Enter the following registration data:

- Registration number
- Date the trial was registered
- Date the trial began





- If you have grant support, select **YES**.
- Identify the support in the Support Details text box. (Example: NIH Grant EY01234)
- If you do not have grant support, select **NO**.
- You must enter **None** in the Support Details text box.

* SUPPORT
If you have grant support, select Yes from the dropdown, then identify the support in the field below.
If you have no grants or support to list, you must select "No" from the dropdown.
None selected
If you selected Yes above, you must identify the support in the Support field below (example: NH Grant EY01234).
* If you selected No above, you must enter (or equiv/paste) None in the Support field below. For output consistency, please enter or convipaste the word None exactly as formatted here; do not use n/a, no, none
Previous Step           Save         Save & Continue >



## **Session** Moderator





#### Authors

<ul> <li>Hide All Amiliations</li> </ul>		Reorder Affiliations
UTHOR		REMOVE
ORDER FIRST AUTHO	OR AUTHORS	AUTHOR
~	Mouse Test - More Info	
	Disclosure	
	* Click to review and acknowledge Disclosure 🗹	
	+ Show Affiliations	
	*Affiliation #1 1	
	ARVO	
	C Edit × Remove	
	Affiliation #2 <b>0</b>	
	None selected	
	* Membership Type	
	Member-in-Training (MIT)	
	* Gender	
	Female 🔹	



- Your name will pre-populate as the First Author on the abstract.
- Click More Info to check your Author Information, scrolling down to confirm your correct email for receiving abstract notifications.
- Corrections to Name and Email must be made in your submission account record, accessed through your name at the top of each submission site page.

AUTHOR		
ORDER	FIRST AUTHOR	AUTHORS
	•	Mouse Test - More Info Disclosure * Click to review and acknowledge Disclosure I
		+ Show Affiliations
		*Affiliation #1 🚯
		ARVO v
		I Edit ★ Remove
		Affiliation #2 <b>1</b>
		None selected •
		* Membership Type
		Member-in-Training (MIT)
		* Gender
		Female •
		* Gender Female

* City	Rockville		
* Country	United States •	)	
* State/Province	Maryland		
Zip/Postal Code	20852		
Phone	2402212932	$\sim$	
Fax			
* E-mail	lbirks@arvo.org		
< Close	Sa	ave & Continue >	



#### **Commercial Relationship Disclosures**

All financial relationships with commercial interests relevant to the research reported in the abstract must be disclosed.

- As First Author, it is your responsibility to provide all commercial relationship disclosures for yourself and your spouse/partner and each of your co-authors during this step of the abstract submission process.
- All relevant disclosures regarding financial relationships with a commercial interest(s) must be reported (i.e. disclosures related to the research reported in the abstract), as well as non-remunerative positions that may create a conflict of interest.
- If you and your spouse/partner or a co-author do not have any commercial relationship disclosures related to the abstract, you must indicate: N (No Commercial Relationship) for that author.



#### **Commercial Relationship Disclosures, cont. Glossary of Disclosure Terms**

O **Commercial Interest:** Any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Providers of clinical service directly to patients are not considered commercial interests.

o **Financial Relationships:** Relationships in which the individual and/or the First Author's spouse/partner benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ARVO considers relationships of the First Author to include financial relationships of a spouse or partner.

0 **Relevant Financial Relationships:** Financial relationships in any amount which occurred in the 12-month period preceding the submission of an abstract, and those which relate to the content of the abstract.

• **Conflict of Interest:** ARVO considers financial relationships to create conflicts of interest when individuals have both a financial relationship with a commercial interest and the opportunity to affect the content of the abstract.

#### **Commercial Relationship Disclosures, cont.**

- Refer to the <u>ARVO Commercial Relationships Policy</u> for disclosure codes and definitions.
- Select Click to review and acknowledge Disclosure

## **Commercial Relationship Disclosures, cont. Scroll**

#### down to enter your disclosure information.

Author Disclosures		
Lorraine Birks		
<mark>≇ Edit</mark> * = Required Fields		
* Commercial Relationship(s) Disclosure		
For this account, disclose the name(s) of the firm(s) with whic	ch commercial relationship(s) exist, as	s well as the applicable Disclosure Codes that relate
<ul> <li>If you do have relationships to disclose, type in the name</li> </ul>	ship(s) Policy and Disclosure Codes of the affiliation, company or institution	definitions. on and select the appropriate dropdown.
Provide one Company Name and one Commercial Relati     For Disclosure Code P, you must provide patentiace	ionship Code per line.	
<ul> <li>For Disclosure Code P, you must provide patenticom</li> <li>For Disclosure Code E, you must provide the compar</li> </ul>	ipany name or patent ID Number. ny name.	
If you do not have any relationships to disclose, click the	No Commercial Relationship radio bu	utton.
<ul> <li>I have one or more of the following Commercial Relation</li> </ul>	nship(s) to disclose:	
F (Financial Support) - Through employing institution s grants or research materials or services at no cost, for s	support from a for-profit company, or o subject of presentation.	competing company, in the form of research funding
I (Personal Financial Interest) - Investor in a company product, service, process or equipment that is the subject	or competing company, other than a ct of presentation.	mutual or retirement fund, which provides a
E (Employment) - Employee of a company or competin	ng company with a business interest t	hat is the subject of presentation.
C (Consultant) - Currently, or within the last 24 months business interest that is the subject matter of presentativ	prior to date of submission, a consultion.	tant for a company or competing company with a
P (Patent) - Inventor/developer designated on a patent, otherwise commercialized, which is the subject matter o	patent application, copyright, or trade of presentation or could be in competi	e secret, whether or not presently licensed or tion with the technology described.
R (Recipient) - Received gifts in kind, honoraria or trave competing company which provides a product, service,	el reimbursement valued in any amou process or equipment that is the subj	int in the last twelve months from a company or ject of presentation.
S (Non-remunerative) - A position(s) of influence uch the person involved in the CME activity to include finance	None selected Sode F (Financial Support) Sode I (Personal Financial Interest)	bkesperson, etc. ARVO considers relationships of r, or a dependent child.
N(No Commercial Relationship) - There is no comme Company Name	Code E (Employment) Code C (Consultant) Code P (Patent) Code R (Recipient) Code S (Nen remunerative)	ct matter of presentation
	(Internet and Control of the control	1
	None selected	
Company Name	None selected   Commercial Relationship(s) Code	



journalofvision.org | tvstjournal.org

## **Commercial Relationship Disclosures, cont.**

#### To report disclosure(s)

- Select 'I have one or more of the following Commercial Relationship(s) to disclose'.
- List each commercial relationship company and its corresponding Relationship Code on a single line.
- If you list a company name multiple times to identify multiple disclosure codes, copy and paste the name from the first entry to ensure an identical company listing that will eliminate duplicate company listings in publications.
- If selecting "P" (inventor/developer) you must add patent/company name or patent ID number.
- If you are employed by a company, you must select "E" and <u>enter the name of the company.</u>

<ul> <li>For Disclosure Code E, you must provide t</li> <li>If you do not have any relationships to disclos</li> </ul>	he company name. e, click the No Commercial Relationship radio butto
I have one or more of the following Commerce	cial Relationship(s) to disclose:
F (Financial Support) - Through employing grants or research materials or services at ne	institution support from a for-profit company, or con o cost, for subject of presentation.
I (Personal Financial Interest) - Investor in product, service, process or equipment that i	a company or competing company, other than a mu s the subject of presentation.
E (Employment) - Employee of a company	or competing company with a business interest that
C (Consultant) - Currently, or within the last business interest that is the subject matter of	24 months prior to date of submission, a consultan f presentation.
P (Patent) - Inventor/developer designated on otherwise commercialized, which is the subject	on a patent, patent application, copyright, or trade se act matter of presentation or could be in competition
R (Recipient) - Received gifts in kind, honor competing company which provides a product	aria or travel reimbursement valued in any arrount i ct, service, process or equipment that is the subject
S (Non-remunerative) - A position(s) of influ	ience such None selected
the person involved in the CME activity to inc	Code F (Financial Supert) Code I (Personal Financial Interest)
N (No Commercial Relationship) - Three is	Code E (Employment)
* Company Name	Code P (Patent)
Company Name	Code R (Recipient)
	Code S (Non-remunerative)
	None selected
Company Name	Commercial Relationship(s) Code
	None selected

## Commercial Relationship Disclosures, cont. Adding Spouse/Partner Disclosures for First Authors

#### If a First Author's spouse/partner has any relevant relationship(s) to disclose:

- Provide all disclosures for the First Author first, followed by any spouse/partner disclosures, if applicable.
- Type in 'Spouse' OR 'Partner', hyphen, and the name of the affiliation, company or institution for each disclosure.
  - Sample formats: Spouse – Genentech Partner – Genentech



- Select the appropriate Disclosure Code from the dropdown.
  - Select Save & Continue at the bottom of the page.





#### **Commercial Relationship Disclosures, cont.**

- If you and your spouse/partner have no disclosures to report
  - Select N (No Commercial Relationships)
- Select Save & Continue at the bottom of the page.

#### \* Commercial Relationship(s) Disclosure

For this account, disclose the name(s) of the firm(s) with which commercial relationship(s) exist, as well as the applicable Disclosure Codes that relate to the support. Click here for the ARVO Commercial Relationship(s) Policy and Disclosure Codes definitions.

- · If you do have relationships to disclose, type in the name of the affiliation, company or institution and select the appropriate dropdown.
- · Provide one Company Name and one Commercial Relationship Code per line.
- For Disclosure Code P, you must provide patent/company name or patent ID Number.
- · For Disclosure Code E, you must provide the company name.
- If you do not have any relationships to disclose, click the No Commercial Relationship radio button.

I have one or more of the following Commercial Relationship(s) to disclose:

F (Financial Support) - Through employing institution support from a for-profit company, or competing company, in the form of research funding, grants or research materials or services at no cost, for subject of presentation.

I (Personal Financial Interest) - Investor in a company or competing company, other than a mutual or retirement fund, which provides a product, service, process or equipment that is the subject of presentation.

E (Employment) - Employee of a company or competing company with a business interest that is the subject of presentation.

C (Consultant) - Currently, or within the last 24 months prior to date of submission, a consultant for a company or competing company with a business interest that is the subject matter of presentation.

P (Patent) - Inventor/developer designated on a patent, patent application, copyright, or trade secret, whether or not presently licensed or otherwise commercialized, which is the subject matter of presentation or could be in competition with the technology described.

R (Recipient) - Received gifts in kind, honoraria or travel reimbursement valued in any amount in the last twelve months from a company or competing company which provides a product, service, process or equipment that is the subject of presentation.

S (Non-remunerative) - A position(s) of influence such as officer, board member, trustee, spokesperson, etc. ARVO considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner, or a dependent child.

N (No Commercial Relationship) - There is no commercial relationship relevant to the subject matter of presentation

Association for Research ision and Ophthalmology

.org | tvstjournal.org

< Close Window

Save & Continue >

#### **Affiliations for Publication**

- From the Affiliation drop-down for each author, select an existing institution or select Create New Institution.
- Repeat for adding a maximum of two Affiliations for each author.
- If there are 2 or more Departments at the same Institution represented, enter each Department/Institution pair separately.
- If 2 or more authors are affiliated with the same Institution / Department, enter that Institution / Department only once and select it for each author.





## Affiliations for Publication, cont.

#### If you select an existing institution:

- You must then select the "Edit" option to review the \*institution, department, \*city, \*state/province and \*country that will be used for all meeting materials.
- \*An error message will occur prior to submission if \*required fields are not completed.
- Note: Data fields for your institution from your account's General and Contact information may not have auto-updated here if you previously updated your account.

	R AUTHORS
	Lorraine Birks - More Info Disclosure Click to review and acknowledge Disc
	Hide Affiliations     *Affiliation #1      Edit
$\searrow$	None selected
$\searrow$	Create New Institution
	None selected



#### Affiliations for Publication, cont.

- If you do not want to use the institution from your account <u>for any author listed</u> in your submission:
  - Select it from the Affiliation drop-down and click 'X Remove' to delete it from your submission.
  - This will not delete it from your account.

R	AUTHORS		
	Lorraine Birks - More Info Disclosure Click to review and acknowledge Disc	sc	
	Hide Affiliations     Affiliation #1    Edit		
	None selected  None selected  Create New Institution  ARVO		
	None selected	<b>ARV</b>	7
		The Association for Rese in Vision and Ophthalmo	earch

## **First Author Membership Type**

- Membership Type must be selected for First Author.
- Select Member-in-Training or Regular.

FIRST AUTHOR	AUTHORS
•	Lorraine Birks - More Info Disclosure Click to review and acknowledge Disclosure 🖉
	- Hide Affiliations
	*Affiliation #1 <b>1</b> Edit
	ARVO T
	I ∉ Edit ¥ Remove
	Affiliation #2 1 Edit
	None selected
	I Edit ★ Remove
	Membership Type 🚯 Edit
	None selected
	None selected Member-in-Training (MIT) Regular
	<ul> <li>Hide Affiliations</li> <li>Affiliation #1  Edit         <ul> <li>ARVO</li> <li>Edit</li> <li>ARVO</li> <li>Edit</li> <li>Remove</li> </ul> </li> <li>Affiliation #2  Edit         <ul> <li>None selected</li> <li>Edit</li> <li>None selected</li> <li>Membership Type  Edit</li> <li>None selected</li> <li>None selected</li> <li>Member-in-Training (MIT) Regular</li> </ul> </li> </ul>



## **Abstract Submission: Step 4: Authors, cont.** First Author Gender

• Gender must be selected for First Author.

<hr/>	* Membership Type		
	Member-in-Training (MIT)	*	
La construction of the second s	* Gender		
	Female	*	
	None selected		
	Female		
	Male		



## Add an Author

 Select Add Author to search the submission site accounts and add up to fifteen (15) co-authors to your abstract.

UNDER	FIRST AUTHOR	AUTHORS
	~	Mouse Test - More Info Disclosure * Click to review and acknowledge Disclosure Z
		+ Show Affiliations
		*Affiliation #1 <b>()</b>
		ARVO *
		C Edit × Remove Affiliation #2
		None selected
		None selected  * Membership Type
		<ul> <li>None selected</li> <li>Membership Type</li> <li>Member-in-Training (MIT)</li> </ul>
		<ul> <li>None selected</li> <li>Membership Type</li> <li>Member-in-Training (MIT)</li> <li>Gender</li> </ul>



#### w.iovs.org | journalofvision.org | tvstjournal.org

## Add an Author, cont.

- First search by Last/Family Name.
- If not found by Last/Family Name, search by Author's E-mail.

C Update Author Order	+& Add Author		Search by
Search for Author to A	dd		Last Name OR
First/Given Name	Last/Family Name	Author's E-mail Email@Example.som	Email
Q Search			
			The Association for Research in Vision and Ophthalmology

#### Add an Author, cont.

- Select Add to add an author from the Author Search Results.
- <u>Select</u> 'More Info' next to their name to confirm/update contact information.
  - Scroll down from the right to provide all required information.
  - IMPORTANT: If you receive an error message that says "Institution: City Missing", click the More Info link next to each author's name and scroll down to make sure that all author details are included for submission.

Search for Author to	Add (a minimum of 1 field	below is required)	
First/Given Name	Last/Family Name abdala	Author's E-mail Email@Example.com	
Q Search	2 Search thor Search Results (2 Authors Found)		
ADD NAME	DEPARTMENT	INSTITUTION	E-MAIL
Abdala,		Instituto de Oftalmologia Conde de	alex_abdala@ho
More Info		Valenciana	
+ Abdala, Carlos	Ophthalmology & Visual	Unidad Laser Clinica Oftalmologica	cabdala@unidad
Add More Info	Science		
Cancel Create An	Author		

## Add an Author, cont.

- Select Create An Author if the author cannot be found by Last Name or by Email.
- First name, last name, city, country, state/province for US, Canada, Australia, and email are required fields designated with a red \*.
- Select Submit Created Author

First/G	iven Name	Last/Family Nan	ne Author's E-mail	
		abdala	Email@Example.co	m
Q Se	earch			
Autho	or Search Results	(2 Authors Found)		EMAIL
+ Add	Abdala, Alexandra More Info		Instituto de Oftalmologia Conde o Valenciana	de alex_abdala@hotmail.com
+ Add	Abdala, Carlos More Info	Ophthalmology & Visual Science	I Unidad Laser Clinica Oftalmologic	ca cabdala@unidadlaserdelatlantico.co
Canc Crea * = * =	te An Author Required for al Required for Pr Required for C	Author I Authors resenter ontact Author		
Crea * = * = * =	Create An A te An Author Required for al Required for Co	I Authors resenter ontact Author		Ω Add Special Charac
Canc Crea * = * = * = Prefix	create An A create An Author Required for all Required for Pr Required for Co content of the Author Required for Content Required for C	Author resenter contact Author		
Crea * = * = Prefix Nor	Create An A te An Author Required for al Required for Pr Required for Co content of the selected to the select	Author resenter ontact Author	ddle	Ω Add Special Charac
Crea * = * = Prefix Non * First	Create An A create An Author Required for all Required for Pr Required for Co content of the selected to	Author I Authors resenter ontact Author Mite	ddle	Add Special Charac     Last/Family Name
Canc Crea * = * = Prefix Non * First Suffix	Create An A Required for al Required for Pr Required for Cr c c to selected to the c c c c c c c c c c c c c	Authors I Authors resenter ontact Author Mid	ddie dress 2	Add Special Charac     Last/Family Name
Crea * = * = * = Prefix Nor • First Suffix Addre	c Create An Author Required for al Required for Pr Required for Cr c c c c c c c c c c c c c c c c c c c	Author  I Authors resenter ontact Author  Mid	ddle dress 2 ate/Province	Ω Add Special Charac • Last/Family Name Zip/Postal Code
Creat Creat Creat Prefix Prefix Prefix Addre City Cou	Create An A Required for Pi Required for Pi Required for Co consecutive to the selected to the selected t	Authors I Authors resenter ontact Author Mic	ddle dress 2 ate/Province	Add Special Charac     Last/Family Name Zip/Postal Code
Creat Creat Creat Creat Prefix Norr First Suffix Addrec Cou Norr	Create An A Required for Pi Required for Pi Required for Co conserved for Co co	Authors I Authors resenter ontact Author	ddle dress 2 ate/Province	Add Special Charac     Last/Family Name Zip/Postal Code



Add an Author, cont. For each added Co-author:

- Provide Disclosures for commercial relationships related to the abstract.
- Add their affiliation(s)
- Give your co-authors their correct order number as they should be listed in the abstract.
- Select Update Author Order.
- Make sure that ALL AUTHORS are INCLUDED in your abstract and are IN THE PROPER ORDER.

You will not be able to add authors or make any changes after the modification deadline of Sunday, December 2, 2018, 11:59pm U.S. EST. **No exceptions**.

2 🔻	Alexandra Abdala - More Info Disclosure	× Remove
•	Click to review and acknowledge Disclosure	
Ť	Hide Affiliations	
1	*Affiliation #1 0 Edit	
	None selected	
	li i i i i i i i i i i i i i i i i i i	
	Affiliation #2 🛛 Edit 📈	
	None selected	
	l Gelit ★ Remove	
V		
C Undate Author	Order + Add Author	



## **Study Group**

- Provide a Study Group name, if applicable.
- Additional authors may **not** be added to the Study Group text box **they** will be deleted.
- When finished, select Save & Continue.

CUpdate Author Order	hor		
Study Group Please enter your study group in the box be	ow. Do not use "the", "for the", or "on	1 behalf of."	1
Previous Step		Save Save & Continue >	The Association for Research in Vision and Ophthalmology

## **Abstract Submission: Step 5: Affirmations**

# You will be required to acknowledge these affirmations by selecting each box during abstract submission.

- First Author must receive approval from the Principal Investigator for submission of the work in the abstract for presentation at the 2020 ARVO Annual Meeting.
- First Author is obligated to register and pay the fees to attend the 2020 Annual Meeting if the abstract is accepted for presentation.
- First Author must be the presenting author at the Annual Meeting and present the same work submitted in the abstract.
- The abstract represents data and conclusions not previously published nor previously
  presented at ARVO by the same investigator, nor is it redundant with abstracts submitted
  to ARVO in the same year by the same group of investigators.
- First Author must reveal the essential structure (DNA sequence), the elements of a novel compound, or sufficient identification of new gene compounds (drugs, genes, etc.) in the presentation, if applicable.



## **Abstract Submission: Step 5: Affirmations, cont.**

 First Author acknowledges that the abstract will be made available on the ARVO website and then published in the ARVO open access journal *Investigative Ophthalmology & Visual Science* under the Creative Commons <u>Attribution-NonCommercial-NoDerivatives License and that</u> the authors retain copyright, subject to the rights granted to ARVO described in paragraphs 6 and 7 of the ARVO License to Publish

– OR

that the abstract is a work of authorship prepared as part of the author's official duties as an officer or employee of the U.S. Government, and is, therefore, in the public domain. Should the abstract be determined as copyrightable, the authors retain copyright, subject to the rights granted to ARVO described in paragraphs 6 and 7 of the ARVO License to Publish.

 If experimental animals were used in investigation, any research reported was conducted in compliance with the <u>ARVO Statement for the Use of Animals in</u> <u>Ophthalmic and Visual Research</u>.



## Abstract Submission: Step 5: Affirmations, cont.

- If human subjects were involved in the investigation, any research reported was conducted in compliance with the "Declaration of Helsinki".
  - (1<sup>st</sup>) the research followed the tenets of the Declaration of Helsinki;
  - (2<sup>nd</sup>) informed consent was obtained from the subjects after explanation of the nature and possible consequences of the study; and
  - (3<sup>rd</sup>) where applicable, the research was approved by the institutional human experimentation committee or institutional review board (IRB).
- First Author understands ARVO's requirement to register a clinical trial prior to reporting on the trial in compliance with <u>ARVO's Clinical Trials</u> <u>Policy</u>



# **Abstract Submission: Step 5: Affirmations, cont.**

## **Continuing Medical Education (CME) Attestations**

- To assist ARVO in determining which sessions may be eligible for CME credit, you are required to respond with Yes or No to the following statements.
- Yes or No responses <u>will not</u> be a factor in the acceptance or rejection of submissions.
- Questions regarding these CME-related statements should be directed to <u>education@arvo.org</u>.
  - I agree to prepare and present content that promotes improvements or quality in research and/or healthcare and not a specific proprietary business interest or commercial interest.
  - I agree to prepare and present content that is free from commercial influence, is based upon scientific methods generally accepted by the scientific and/or medical community, and is only for educational/scientific purposes.

The Association for Research in Vision and Ophthalmology

## **Abstract Submission: Step 6: Review & Submit**

#### **Review all Submission Input**

Carefully check each Step of your submission data listed on the page.

- Make sure all special characters and formatting are displaying properly.
- If you find errors, return to the appropriate Step by clicking the Edit option next to that Step's heading on the page or in the left sidebar.

cate New Submissio	Deadline: Dec 5, 2014 11:59 PM U.S. EST Total Characters: 230 out of 2500 C Full Instruct	ions 🗗		
Step 1: Submission type	Daview Submission Input			
Step 2: Title/Body	Carefully sheek each atop of your submission data listed on the page			
Step 3: Details	<ul> <li>Carefung view each step of your submission data insets on the page.</li> <li>Make sure all special characters and formatting are displaying property.</li> </ul>	0 sidahas		
tep 4: Author	<ul> <li>If you indervors, recurs to the appropriate step by clicking the concoption next to that step's neading on the page of in the re View Proof</li> </ul>	it sidebar.		
Step 5: Affirmations	View the proof of your abstract for a user-friendly layout of your abstract submission and the option to print it as a PDF			
Step 6: Review & Submit	<ul> <li>If you identify errors, close the window to return to Review &amp; Submit, and then select the appropriate step to return and mak corrections.</li> </ul>	e any		
	Submitting Your Abstract			
	Only abstracts in "submission" status on Sunday, December 7, 2014, 11:59 pm U.S. ET will be reviewed praceptance.     A system-generated entil will be sent to confirm that your submission abstract has been submitted, using the email in your submission     To make updates to an abstract in "Submission" status, return it to "Draft" status from the View Submissions left sidebar, ma changes, and "Submit" it again prior to the Sunday, December 7, deadline.     ZEhit     * = Required Fields	site account. Ike the		
	* Review Submission Input			
	Step 1: Submission type			
	Abstract Submission			
	✓ Step 2: Title/Body IZ Est			
	SECTION VALUE			
	Title TEST title - Image Issue, Multiple Authors			
	Purpose Images and Image Captions – Step 8 Abstracts may include up to two images (tables, graphs, figures, etc.).			
	Methods test methods			
	Results test results			
	Conclusions test conclusions			



## Abstract Submission: Step 6: Review & Submit, cont.

#### **Incomplete Steps**

 Incomplete Steps, if any, will be listed under Review Submission Input and hyperlinked for you to return and provide the missing required information, save at the bottom of that Step (you will now see a **check mark** beside the Step that you just completed), and return to the Review & Submit Step.



www.arvo.org | www.iovs.org | journalofvision.org | tvstjournal.org

in Vision and Ophthalmology

## Abstract Submission: Step 6: Review & Submit, cont. View and Print Abstract Proof

- You will also want to View the Proof of your abstract for a user-friendly view of your abstract submission and the option to print it as a PDF.
  - Use the View Proof link at the bottom of the page.
  - Again, if you identify errors, Close the Window to return to Review & Submit, and then select the appropriate Step to return and make any corrections.

community, and is only for educational/scientific purposes.	View Abstract
View Proof	CONTROL ID: 2087714
The proof is the final version of your submission, based en the society's guidelines.	SUBMISSION ROLE: Abstract Submission AUTHORS AUTHORS (LAST NAME, FIRST NAME): <u>Birks, Lorraine<sup>1</sup></u> INSTITUTIONS (ALL): 1. ARVO, Rockville, MD, United States. Commercial Relationship Disclosure (Abstract): Lorraine Birks: Commercial Relationship: Code N (No Commercial Relationship) Study Group:
	ABSTRACT TITLE: TEST abstract ABSTRACT BODY: Purpose: test purpose with 12 <sup>th</sup> and Ā special character test.
Previous Step	Methods: test methods Results: test results
	Conclusions: test conclusions

## Abstract Submission: Step 6: Review & Submit, cont.

#### **Abstract Submission**

- When all Steps are complete, the Submit button will display at the bottom of the Review & Submit page to allow you to submit the abstract.
- Abstracts must be submitted by the modification deadline of Sunday, December 8, 2019, 11:59 pm U.S. ET.



## Abstract Submission: Step 6: Review & Submit, cont.

#### Abstract Submission, cont.

- Upon successfully submitting your abstract, you will be returned to View Submissions with a green Success! message displayed at the top of the page.
- A system-generated email will be sent to confirm that your abstract has been submitted, using the email in your submission site account.

	ARVO2017 GLOBAL CONNECTIONS IN VISION RESEARCH   MAY 7 - 11   BALTIMORE SUBMISSION SITE Abstract submission open Oct. 15 - Dec. 2, 2016, 11:59 U.S. EST
Welcome Submission	
View Submissions	Success! Your submission was successfully submitted.
Create New Submission	View Submissions
	The Association for Research in Vision and Ophthalmology

## **Abstract Submission - View Drafts & Submission**

Select View Submissions from the left sidebar to access your abstract Drafts and/or Submission.

~	View Submissions	View Su	bn	nission	IS							
	Create New Submission >	Submission Opening October 1	Ins	tructions	5							
		ABSTRACT SUBM SIG SUBMISSIONS	ISSIO	NS								
		INVITED SPEAKER SUBMISSIONS DUE: Monday, October 6, 2014, 11:59 pm U.S. EST is the due date for submissions to be finalized from Draft to Submission status								IS		
		If you have beer     If you are preser     DO NOT CREA     DO NOT DELET     Scroll down to th     Click the drop-d     Please carefully     right corner of e	n invite nting in TEAI TEAN he bot lown a read sach su	ed to speak dur n more then on NEW INVITED Y INVITED SP tom of this page nd select Edit [ over the Full In ibmission step!	ing ARVO 20 e invited spe SPEAKER S EAKER DR/ e to access y Draft to begin structions to s page.	015, a d eaker se SUBMIS AFT(S) your Invi in your e before b	Iraft submit ession, eac SSION. that have to that have to that have to the second edits. reginning to	ssion has alre h draft submis been started fo er Submission o edit your pre	ady been s ssion will be or you. n draft. esentation o	started for you. e available below. draft. Full Instructions	are located in the to	P
	TECHNICAL SUPPORT Monday 12:00am U.S. Eastern Time through Friday 8:30pm U.S. ET. Email: ts.acsupport@thomson.com Phone: +1.434.964.4100 (toll-free U.S. only: 888.503.1050)											
		POLICY AND PROCEDURES SUPPORT Monday through Friday, 8:30am-6:00pm U.S. ET. Email: arvoabstracts@arvo.org Phone: +1.240.221.2900										
		C Edit										
				TITLE			ID	MODIFIED		DEADLINE	TYPE	
	-	Select	۲	TEST title - Ir Multiple Auth	mage Issue, ors		2091497	Oct 7, 2014 U.S. EST	3:18 PM	Dec 5, 2014 11:59 U.S. EST	PM Abstract Submission	
		Submissions										
		ACTION		TITLE	ID	SUB	NITTED		DEADLI	NE	TYPE	The Association for Descerat
	<b>^</b>	Select	•	TEST abstract	2087714	Oct 7, EST	, 2014 3:21	PMU.S.	Dec 5, 20 EST	014 11:59 PM U.S.	Abstract Submission	in Vision and Ophthalmology

www.arvo.org | www.iovs.org | journalofvision.org | tvstjournal.org 59

## **Abstract Submission – Revisions**

- To revise your submission or draft, use the same Abstract Submission Link at the bottom of the <u>Abstracts</u> web page to return to the Submission Site.
- From the Submissions tab select View Submissions; scroll to the bottom of the page; select Edit for that abstract.

			2017	Oct. 15		
Welcome	Submission					
View Sub	missions	View Su	bmissions			
Create Ne	w Submission	2017 Annua	al Meeting Sub	missions		
Drafts			Drafts			
ACTION	TITLE ID	MODIFIED	ACTION	I TITLI	E ID	MODIFIED
Select	2638270	Oct 14, 2016 11:28 EST	Select		2638270	Oct 14, 2016 EST
Edit Draft View E-mails			Submis	sions		
Delete			ACTION	I TITLI	e ID	SUBMITTED
CTION	TITLE ID	SUBMITTED	Select	TEST	2638305	Oct 14, 2016
Select	TEST 2638305	Oct 14, 2016 1:40 F EST	Select View A View E	bstract -mails		ESI
			Edit / R	leturn to Draft		



## **Abstract Submission – Revisions, cont.**

- If returning a Submission to Draft status for revisions, Select Yes to proceed.
- You will receive a system-generated email to confirm that your abstract has been returned to Draft status.
- Abstracts returned to Draft status must be re-submitted by the modification deadline of Sunday, December 8, 2019, 11:59 pm, U.S. ET, to be considered for review.
- No changes or submissions will be allowed after the modification deadline.

View Submissions	View Submissions		
Create New Submission	Submission Instructions		
	Move to Draft status? You will need to resubmit the file to qualify for review. Are you sure you want to more you want to more submit in Draft statur?	× be finalized for your be available to	
	Ko, Do Not Move     Yes, Move to Draft 3	on draft. Fuil In.	
			The Association for Resea in Vision and Ophthalmolo
		s.org   jouri	nalofvision.org   tvstjournal.

org

## **Abstract Submission – Revisions, cont.**

- Your abstract now appears in the Drafts section of the View Submissions page.
- To make revisions, select Edit Draft.
- When your edits are completed, you must **Resubmit** the abstract again by the modification deadline of Sunday, December 8, 2019, 11:59 pm U.S. ET.
- You will receive another system-generated email confirming the resubmission of your abstract.
- Only abstracts with a Submission status at the modification deadline will be sent forward for review.

ACTION	TITLE	ID	MODIFIED	DEADLINE	TYPE
Select ¥	TEST abstract	2087714	Oct 7, 2014 4:19 PM U.S. EST	Dec 5, 2014 11:59 PM U.S. EST	Abstract Submission
 Select	TEST title - Image Issue, Multiple Authors	2091497	Oct 7, 2014 3:18 PM U.S. EST	Dec 5, 2014 11:59 PM U.S. EST	Abstract Submission



## **Abstract Submission Confirmations & Email Updates**

# Abstract submission confirmations will be emailed to First Authors on Wednesday, December 11, 2019.

- This confirmation and all other abstract-related correspondence will be sent to the First Author's email address provided in their submission site account.
- To endure delivery of your abstract-related communications, add <u>ts.acsupport@clarivate</u> <u>and arvoabstracts@arvo.org</u> to your email address book or Safe Sender White List to facilitate delivery and avoid firewalls and spam filters. If you're unsure of how to add to your Safe Sender White List, contact your email administrator.

If you updated your name or email in your Submission Site account, you must also submit those updates to <u>arvo@arvo.org</u> to update your membership account record as well.

 If you return to the Submission Site later, your name and email from your membership account will overwrite any name/email updates you made.

